

## Strain heterogeneity in a non-pathogenic fungus highlights factors contributing to virulence

David C. Rinker<sup>1</sup>, Thomas J. C. Sauters<sup>1</sup>, Karin Steffen<sup>1</sup>, Adiyantara Gumilang<sup>1</sup>, Huzeifa A. Raja<sup>2</sup>, Manuel Rangel-Grimaldo<sup>2</sup>, Camila Figueiredo Pinzan<sup>3</sup>, Patrícia Alves de Castro<sup>3</sup>, Thaila Fernanda dos Reis<sup>3</sup>, Endrews Delbaje<sup>3</sup>, Jos Houbraken<sup>4</sup>, Gustavo H. Goldman<sup>3\*</sup>, Nicholas H. Oberlies<sup>2\*</sup>, Antonis Rokas<sup>1\*</sup>

<sup>1</sup> Department of Biological Sciences and Evolutionary Studies Initiative, Vanderbilt University, Nashville, Tennessee, USA

<sup>2</sup> Department of Chemistry and Biochemistry, University of North Carolina at Greensboro, Greensboro, North Carolina, USA

<sup>3</sup> Faculdade de Ciencias Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil

<sup>4</sup> Food and Indoor Mycology, Westerdijk Fungal Biodiversity Institute, Utrecht, The Netherlands

\*Corresponding authors:

Gustavo H. Goldman (ggoldman@usp.br)

Nicholas Oberlies (n\_oberli@uncg.edu)

Antonis Rokas (antonis.rokas@vanderbilt.edu)

## ABSTRACT

Fungal pathogens exhibit extensive strain heterogeneity, including variation in virulence. Whether closely related non-pathogenic species also exhibit strain heterogeneity remains unknown. Here, we comprehensively characterized the pathogenic potentials (i.e., the ability to cause morbidity and mortality) of 16 diverse strains of *Aspergillus fischeri*, a non-pathogenic close relative of the major pathogen *Aspergillus fumigatus*. *In vitro* immune response assays and *in vivo* virulence assays using a mouse model of pulmonary aspergillosis showed that *A. fischeri* strains varied widely in their pathogenic potential. Furthermore, pangenome analyses suggest that *A. fischeri* genomic and phenotypic diversity is even greater. Genomic, transcriptomic, and metabolomic profiling identified several pathways and secondary metabolites associated with variation in virulence. Notably, strain virulence was associated with the simultaneous presence of the secondary metabolites hexadehydroastechrome and gliotoxin. We submit that examining the pathogenic potentials of non-pathogenic close relatives is key for understanding the origins of fungal pathogenicity.

## KEYWORDS

comparative genomics, evolution of virulence, fungal pathogenicity, secondary metabolism, specialized metabolism, virulence factor, gliotoxin

## INTRODUCTION

Filamentous fungi of the genus *Aspergillus* cause a spectrum of diseases collectively known as aspergillosis that account for 340,000 fungal infections every year, and impose a heavy burden on human health and health care systems <sup>1-4</sup>. The deadliest infections are invasive in nature, with pulmonary aspergillosis being the most common and most deadly type <sup>5</sup>. Although many species of *Aspergillus* are capable of causing disease, *Aspergillus fumigatus* is the one most frequently seen in the clinic and is considered the primary etiological agent of invasive aspergillosis <sup>6-11</sup>. Consequently, *A. fumigatus* has been the focus of most studies investigating the mechanisms of fungal virulence in aspergillosis cases.

The genomic, transcriptomic, and metabolic components underlying virulence, and more broadly the pathogenic potential (i.e., the ability to cause morbidity and mortality), of opportunistic fungal pathogens defy ready characterization. Because the mammalian host environment is alien to nearly all fungal species, traits facilitating fungal virulence will be exaptations, that is the coopting of adaptations that originally evolved to serve functions other than virulence <sup>12,13</sup>. Traits such as thermotolerance, efficiency and/or flexibility in competing for limited nutritional resources, the ability to grow under hypoxic conditions, as well as the production of an array of secondary metabolites, have all been identified as fungal adaptations to natural challenges that happen to also act as facilitators of opportunistic fungal infections in mammalian hosts <sup>6,13</sup>.

Intraspecific diversity can then further broaden the potential of fungi to (accidentally) cause disease, and is especially pronounced in rapidly evolving organisms, such as filamentous fungi <sup>14</sup>. In *A. fumigatus*, traits such as genotype <sup>15</sup>, chromatin state <sup>16</sup>, hypoxia tolerance <sup>17,18</sup>,

photopigmentation and photoconidiation<sup>19</sup>, secondary metabolite biosynthesis<sup>20,21</sup>, and hypersensitivity to nitrosative or oxidative stresses<sup>22</sup>, all show extensive variation or heterogeneity between strains. Strain heterogeneity is also a known confounder when predicting clinical outcomes of infection, not only in *A. fumigatus* but in other major fungal pathogens, including *Candida albicans*, *Nakaseomyces glabrata*, and *Cryptococcus neoformans*<sup>17,23–26</sup>.

Strain heterogeneity within pathogenic fungal species can be leveraged to identify key traits contributing to virulence and identify virulence-associated loci<sup>27</sup>. Comparative analyses between *A. fumigatus* strains have revealed insights into the relationship between hypoxia tolerance and pathogenicity<sup>17,26</sup> and have shown how gene regulatory differences can result in variable responsiveness to fungistatic drugs<sup>28</sup>.

The relationship between strain heterogeneity and pathogenic potential has been examined in major fungal pathogens but has yet to be examined in non-pathogens. *Aspergillus oerlinghausenensis* and *Aspergillus fischeri* are the two closest known relatives of *A. fumigatus*<sup>29</sup>; each likely sharing a common ancestor with *A. fumigatus* less than 4 million years ago and both considered to be non-pathogenic<sup>20</sup>. While only two strains of *A. oerlinghausenensis* are currently known<sup>30</sup>, *A. fischeri* is globally distributed and can be readily found in the soil, on fruits, on decaying organic matter, and it is a major food spoilage agent<sup>31–34</sup>. *A. fischeri* is not considered a pathogen and only a handful of aspergillosis cases have been attributed to it<sup>6,35–40</sup>. Examining whether strains of non-pathogenic species closely related to major pathogens also vary in their pathogenic potential could inform our understanding of how fungal pathogens originate.

Here we test the hypothesis that strains of a nominally non-pathogenic species exhibit heterogeneity in disease-relevant genes and traits, including in their pathogenic potentials. To this end, we comprehensively characterized the genotypes, chemotypes, and pathogenic phenotypes of 16 *A. fischeri* strains representing different geographic regions and substrates. Using a murine model of pulmonary aspergillosis, we found that *A. fischeri* strains exhibit considerable variation in their virulence profiles and responses to mammalian immune cells. This variation is associated with specific genomic, transcriptomic, and metabolomic differences, suggesting that examination of the pathogenic potential of non-pathogenic close relatives can shed light onto the origins of fungal pathogens.

## RESULTS

### ***A. fischeri* strains elicit wide range of responses to murine macrophages**

To examine the presence, prevalence, and degree of strain heterogeneity in *A. fischeri*, we selected 16 strains of *A. fischeri* representing a diversity of substrates (soil, food) and geographical origins (Europe, Asia, and Africa; Table 1). We used the *A. fumigatus* CEA17 strain, a clinically derived and highly virulent strain, as a reference<sup>29,41</sup>. The growth rate for each strain was measured at both ambient (30°C) and disease-relevant (37°C) temperatures (Methods). All strains grew equally well at 37°C except for one strain (DTO7) and exhibited some variation in pigmented conidiation (Figure S1).


We first examined how conidia (asexual spores) from each strain interacted with murine-derived macrophages (Methods). Overall, conidial survival in the presence of macrophages varied widely

among strains (Figure 1A). While conidia of some strains had very low survival in the presence of macrophages (e.g., strains DTO2, DTO9, and DTO1), the survivability of conidia from several other strains (e.g., DTO7, DTO3, and DTO16) was high; notably, conidia from strain DTO16 were statistically indistinguishable from conidia from the highly virulent CEA17 reference strain of *A. fumigatus* (unpaired two-sample t-test, Bonferroni-corrected p-value > 0.01).

We next measured the pro-inflammatory cytokine responses of macrophages, an *in vitro* proxy for the mammalian innate immune response, to conidia from each strain (Methods). We found a graded, strain-dependent response in macrophage cytokine levels (Figure 1B). Specifically, some of the cytokine responses elicited by certain strains (e.g., DTO12, DTO14, DTO3, and DTO16), rivaled the responses elicited by the *A. fumigatus* CEA17 strain. Indeed, certain *A. fischeri* strains elicited levels of IL-1 $\beta$  and/or TNF- $\alpha$  that surpassed those elicited by the *A. fumigatus* CEA17 strain (e.g., DTO3, DTO12, DTO14, DTO16); these differences were not statistically significant (all unpaired two-sample t-tests, false discovery rate-corrected p-value > 0.01).

Overall, there was a general concordance between strains that were more resistant to macrophages and those inducing higher levels of proinflammatory cytokines (Figure 1). Notably, there was a large difference in both assays between the macrophage response to conidia from the *A. fumigatus* reference strain CEA17, and those from the *A. fischeri* reference strain NRRL181 (DTO11). Taken together, the conidial challenge assays of 16 strains demonstrate that there exists substantial phenotypic variation within *A. fischeri* that is not reliably reflected by the *A.*


*fischeri* reference strain. Importantly, some levels of conspecific variation are at least on par with levels of interspecific variation.



## *A. fischeri* strains vary considerably in their virulence profiles

The strain heterogeneity of *A. fischeri* observed in the macrophage assays raised the hypothesis that these strains could vary in their pathogenic potential. To test this, we measured the virulence (mortality) of *A. fischeri* strains in a chemotherapeutic murine model of pulmonary aspergillosis (Methods).

We observed substantial variation in virulence across the strains (Figure 2). While no strain of *A. fischeri* exhibited the 100% mortality rate of *A. fumigatus* CEA17, several *A. fischeri* strains (e.g., DTO14, DTO15, DTO12, and DTO16) consistently produced lethality rates of 50% or



greater, and four strains (e.g., DTO14, DTO7, DTO9, and DTO8) resulted in earlier onset of death compared to CEA17. Overall, DTO14 was the deadliest strain, resulting in two deaths after only two days and having the lowest animal survival rate of any *A. fischeri* strain (35% mean survival rate over the two trials). Importantly, there was a large difference in the survival of mice exposed to conidia of the *A. fumigatus* reference strain CEA17 compared to those infected by the *A. fischeri* reference strain NRRL181 (DTO11). This difference in lethality between the two reference strains for each species is consistent with previous results<sup>29</sup>.

### **Genes associated with virulence and secondary metabolism are highly conserved across *A. fischeri* strains**


We next quantified the genetic relationships between these strains and investigated the genomic context of the observed phenotypic diversity. In particular, we evaluated each strain for the presence of 207 genes previously associated with virulence in *A. fumigatus*<sup>29,42,43</sup>. We also assessed intraspecific variation in biosynthetic gene cluster (BGC) content, given the known role played by secondary metabolites in virulence<sup>44,45</sup>. To this end, we constructed chromosome-level *de novo* genome assemblies and built gene models for all 16 strains (Methods).

To evaluate evolutionary relationships between the 16 *A. fischeri* strains, we inferred a strain phylogeny using 3,354 single copy Eurotiomycetes (BUSCOs) orthologs present in all strains (Figure 3A; Methods). We found that *A. fischeri* strains are genetically very similar, with the highest pairwise distance occurring between DTO2 and DTO10 ( $\sim 4 \times 10^{-3}$  nucleotide substitutions/site). This is on a par with the distance between the two *A. fumigatus* strains (Af293 and CEA10, which is a progenitor strain of CEA17<sup>41</sup>) included in our analysis ( $\sim 2.4 \times 10^{-3}$

nucleotide substitutions/site). In contrast, any *A. fumigatus* outgroup strain is over 36 times more diverged (~0.14 substitutions/site) from any *A. fischeri* strain.

To gain insights into the population structure of *A. fischeri*, we performed ADMIXTURE analysis of 215,627 single nucleotide variants (SNVs) that are polymorphic within *A. fischeri* (Methods). These analyses suggested that *A. fischeri* strains can be divided into between 2 and 4 ancestral populations (Figure 3B). This structure is broadly reflective of and consistent with the *A. fischeri* phylogeny (Figure 3A). Further analysis of these SNVs by both discriminant analysis of principal components (DAPC) and principal components analysis (PCA) (Figure 3C and Figure S2, respectively; Methods) consistently identified strains DTO10 and DTO8, as well as DTO2 and DTO7, to be more distinct from the rest, potentially representing populations whose breadth has not been fully captured by our sampling. That said, except for DTO7, these four strains are not notably distinct in terms of their conidial viabilities, cytokine responses, virulence profiles, and overall pathogenic potentials (Figure 2).

Genes from all 16 strains were consolidated into an *A. fumigatus* pangenome comprising 16,148 single-copy pangenomes (Methods). Of the pangenomes, 9,053 are present in every strain (core genes), with the remaining 7,095 in only some (accessory genes) or one (singleton genes) strain (Figure 3D). The accessory gene component of the pangenome is monotonically increasing without converging, a finding indicative of an open pangenome (Figure 3D; Heap's law  $\gamma = 0.85849$ ). Therefore, genome sequencing of additional *A. fischeri* strains will likely reveal more accessory genes.




Among a set of 207 virulence-associated genes previously identified in *A. fumigatus*<sup>46</sup>, orthologs of all but *pesL* (*Afu5g12730*), *fmaG* (*Afu8g00510*), and *fma-TC* (*Afu8g00520*) are present in most, if not all, *A. fischeri* strains. Even the strain that lacks the highest number of virulence-associated genes (DTO6) still contains 201 of them. Our pangenome-based approach provides further support for the inference of Mead et al. that *A. fischeri* possesses most of the virulence-associated genes identified in *A. fumigatus*<sup>29</sup>.

Many of the 207 virulence-associated genes are located within BGCs, reflecting the fact that secondary metabolites are important to fungal lifestyles, including pathogenic lifestyles<sup>13,44</sup>. We examined six previously described *Aspergillus* BGCs that are responsible for the biosynthesis of seven secondary metabolites variously implicated as virulence factors in *A. fumigatus*: gliotoxin, fumitremorgin A/B, verruculogen, trypacidin, pseurotin, fumagillin, and hexadehydroastechrome (Table 2)<sup>20,47</sup>. All the genes for the gliotoxin and hexadehydroastechrome BGCs are present in all strains, while the genes for the trypacidin and verruculogen/fumitremorgin A/fumitremorgin B BGCs are present in all but one and two strains, respectively. The pseurotin and fumagillin BGCs were incomplete (i.e., only some of the genes were present) in all strains. Our expanded taxon sampling highlights the low variability of BGC presence/absence between strains, and augments previous work showing high conservation of BGCs in strains of *Aspergillus* species, including the major pathogen *A. fumigatus*<sup>21,48</sup> and the rare pathogen *A. nidulans*<sup>49</sup>. Overall, these data show that most genomic features associated with virulence in *A. fumigatus* are present in and conserved among *A. fischeri* strains; in turn, this conservation suggests that pathogenic potential cannot be readily attributed to differences in gene content.

### ***A. fischeri* strains show high variation in transcriptional response to elevated temperatures**

The pathogenicity of opportunistic fungi is a result of both their ability to thrive within the host environment and the incidental effects of their responses (e.g., secondary metabolite production) to growth under disease-relevant conditions<sup>13,44,50,51</sup>. To characterize genes that may be active, or may become active, in infection-relevant conditions, we profiled the transcriptomes of each of the strains at 30°C and 37°C (Methods).

Strains showed very diverse transcriptional profiles in response to growth at 37°C. Strain-to-strain comparisons of differential expression profiles do not follow the intraspecific relationships inferred from the strain phylogeny (Figure 4A). For example, the expression profile of strain DTO16 is most similar to those of DTO15 and DTO14, but the strain is not the sister group to the DTO14+DTO15 clade on the phylogeny (Figure 4A). This is not surprising given that transcriptional variation is not expected to always mirror strain evolutionary history.




Examining this temperature-dependent transcriptional response with respect to virulence reveals that the three least virulent strains (DTO1, DTO2, and DTO13; Figure 2) and the three most virulent strains (DTO14, DTO15, and DTO16; Figure 2) group together with three other strains (DTO3, DTO10, and DTO12) based on transcriptional profiles (Figure 4A). Conversely, strains that have identical phenotypes in mouse and macrophage assays are genetically and transcriptionally distinct (DTO10 and DTO4).

No genes are uniquely expressed in either the most- or the least-virulent strains, and only two genes (orthologs of *Afu5g13940* and *Afu6g07260*) are exclusively upregulated in the most virulent strains. While the functional annotations of both genes suggest that they could be involved in secondary metabolite biosynthesis and export (oxidoreductase activity and nucleobase transmembrane transporter, respectively), neither is predicted to be located within a BGC.

Of the 204 virulence-associated genes identified in *A. fischeri*, transcripts for 162 (79%) are detected in all strains, with some strains expressing as many as 186 genes (91%) of the full complement (Figure 4B). In contrast with the global differential expression profiles, the profiles of virulence-associated genes more closely followed the *A. fischeri* phylogeny (Figure 4B). While there appeared some occasional relationship between the presence/absence of virulence-associated gene expression and virulence in mice (e.g., the highly virulent DTO14, DTO15, and DTO16 strains ranked within the top quartile for number virulence-associated genes expressed, while the weakly virulent DTO1 and DTO2 strains were in the bottom quartile), there were plenty of exceptions (e.g., the weakly virulent DTO13 had the highest number of virulence-

associated genes expressed, while the second-to-lowest number of virulence-associated genes were expressed in the highly virulent DTO12).

Expression of genes within the four virulence-associated BGCs present in *A. fischeri* (Table 2) showed pervasive transcriptional activity in most of the strains (Figure 5). Genes in the verruculogen/fumitremorgin A/fumitremorgin B BGC displayed the largest positive changes in their levels of expression in response to the elevated temperature, with DTO9 and DTO12 showing positive regulation across the entirety of the BGC. Genes of the hexadehydroastechrome BGC were also broadly upregulated. Conversely, genes in the trypacidin BGC showed the lowest levels of gene expression; multiple genes were not expressed across the strains and no single strain showed expression for all gene members of the trypacidin BGC. Interestingly, the remaining genes of the otherwise incomplete fumagillin BGC were active and upregulated at 37°C (Figure S3).



**Figure 5: Variation in secondary metabolite production among strains is principally driven by strain diversity** **A.** Chromatograms of the 16 strains of *A. fischeri* displayed three distinct profiles at both 30°C and 37°C temperatures. Shown are representative chromatograms of each profile. The chromatograms report retention times (x-axis) and signal intensities normalized to the highest value (y-axis) of produced metabolites; different peaks correspond to different metabolites. **B.** Principal component analysis based on retention times and individual peak areas for different metabolites from each of the 16 strains following growth at either 30°C or 37°C. Approximately 50% of the variation in the chemistry profiles comes from variation between strains (PC1), and 29% of the variation is due to temperature (PC2). **C.** Temperature-dependent differential expression of transcripts for constituent genes in each of four, virulence-associated biosynthetic gene clusters in 15 *A. fischeri* strains (DTO7 was excluded because of poor growth at 37°C). Secondary metabolite (SM) presence/absence at 30°C and 37°C is indicated to the right of each heatmap. White cells on the heatmap indicate lack of transcriptional activity. HAS: hexadehydroastechrome; tryp: trypacidin; bisGT: bisdethiobis(methylthio)gliotoxin; GT: gliotoxin; verr: verruculogen; fumA: fumitremorgin A; and fumB: fumitremorgin B.

## Variation in secondary metabolite production across strains corresponds to variation in virulence

To evaluate the secondary metabolite profiles of *A. fischeri* strains at 30°C and 37°C, we assayed extracts from cultures of each of the strains by ultraperformance liquid chromatography–mass spectrometry (Figure 5A; Methods). Overall, 30% of the chemodiversity of secondary metabolite profiles was due to growth temperatures (30°C or 37°C) while nearly 50% was attributable to strain heterogeneity (Figure 5B). Some of the most metabolically distinct strains included several of the most- (DTO12, DTO15, DTO16) and least- (DTO1 and DTO2) virulent strains.

We next examined the presence of seven virulence-associated secondary metabolites previously identified in *A. fumigatus* and whose BGCs were also characterized above<sup>20,52</sup>. Four of these virulence-associated secondary metabolites (gliotoxin, hexadehydroastechrome, fumitremorgin A/B, and verruculogen) appeared very frequently or ubiquitously among our strains, while three other compounds (fumagillin, pseurotin, and trypacidin) were not detected.

Examination of the secondary metabolites detected against the virulence profiles across *A. fischeri* strains revealed noteworthy patterns in gliotoxin and hexadehydroastechrome. Gliotoxin was observed in seven strains and its inactive derivative bis(methylthio)gliotoxin was present in all strains (Figure 5B). In the context of infection, gliotoxin acts to suppress the innate immune response in mammalian hosts<sup>53</sup>. *A. fischeri* strains with detectable levels of gliotoxin at 37°C correspond to those showing elevated virulence (greater than 50% mortality) in mice. However, the presence of gliotoxin was not in itself sufficient to predict elevated virulence as gliotoxin was also present in DTO2, the least virulent strain (Figure S4).

Another secondary metabolite detected in only a subset of *A. fischeri* strains was hexadehydroastechrome, an intracellular iron chelator that has been associated with increased virulence in *A. fumigatus*<sup>47,52,54</sup>. In *A. fischeri*, nearly every gene of the hexadehydroastechrome BGC was transcriptionally active in all strains, but the compound was only detected in six strains (Figure 5). Among those six strains, four (DTO12, DTO14, DTO15, and DTO16) showed elevated virulence in mice.

Notably, we detected both hexadehydroastechrome and gliotoxin at 37°C in 3 of the 4 most virulent strains, making their co-occurrence a statistically significant chemical predictor of virulence in a mouse model of pulmonary aspergillosis (binary logistic regression  $\chi^2=7.9913$ ,  $p$  value=0.0047; Figure 5C; Figure S4). We hypothesize that this association may be meaningful to the elevated pathogenic potential exhibited by these strains and may be mechanistically explained by the complementary roles of gliotoxin and hexadehydroastechrome in confounding host defenses, while simultaneously protecting the pathogen. Specifically, gliotoxin blunts active host immune response, and has recently been shown to induce ferroptosis in mammalian cells. Ferroptosis is a form of cell death triggered by aberrantly elevated levels of intracellular iron and can affect macrophages directly<sup>55-57</sup>. Fungi are also susceptible to ferroptosis<sup>58</sup> and the iron chelating property of hexadehydroastechrome could act to protect fungi from a similar fate by sequestering excess iron. None of the other secondary metabolites we detected among our *A. fischeri* strains exhibited this degree of correspondence between their presence/absence (either alone or in combination), and virulence.


## DISCUSSION

The comprehensive characterization of the chemotype, genotype, and pathogenic phenotype of 16 strains of the non-pathogen *A. fischeri* revealed pervasive strain heterogeneity. Of the traits measured, one of the most surprising findings was the range of virulence displayed across strains. In a murine model of pulmonary aspergillosis, mortality ranged from just 10% for the least virulent strain, to infections that killed up to 70% for the most virulent strain. Such variation in lethality between strains of a non-pathogenic species complicates not only how we distinguish pathogenic from non-pathogenic fungal species, but also how specific traits subtending that virulence are disentangled (Figure 6).

Our results show that differences in pathogenic potential in *A. fischeri* cannot be adequately explained by genotype alone, and that they bear closer resemblance to observed differences in overall transcriptomic profiles under certain disease-relevant conditions (Figure 4A). These findings, coupled with the generally high prevalence of *A. fischeri* orthologs of genes previously identified as virulence-associated in *A. fumigatus* (Figure 4B), imply that virulence differences within *A. fischeri* are more likely the result of shifts in gene regulation than of any specific gene content differences.

In pathogenic species of *Aspergillus*, secondary metabolites comprise one of the better characterized sets of virulence factors that can have direct consequences on the host<sup>44,45</sup>. Each of these metabolites is the biochemical output of the protein products of specific BGCs, and one of the ways that metabolite levels can be altered is by the coordinated transcriptional regulation of the genes within the clusters. For example, our *A. fischeri* data show that most genes in the

gliotoxin BGC are pervasively upregulated at 37°C in most strains, and gliotoxin itself is only detected at 37°C in several strains (Figure 5C).



Importantly, the observed strain heterogeneity in secondary metabolism within *A. fischeri* allowed us to identify a statistically significant association between variation in the production of just a few secondary metabolites and the breadth in pathogenic potentials between strains. Specifically, we observed a statistically significant association between strain virulence and the co-detection of gliotoxin and hexadehydroastechrome, raising the hypothesis that the production of just these two secondary metabolites in combination is sufficient for increasing a strain's pathogenic potential (Figure S4). While we are not proposing that any specific secondary metabolite(s) should be credited with the broader gain/loss of a pathogenic phenotype within or across *Aspergillus* species, the strong effect size that can be attributed to the co-presence of just two metabolites offers support for the hypothesis that secondary metabolism-associated "cards" of virulence contribute to the "hand of cards" that enable any given *Aspergillus* strain or species to cause disease<sup>12,20</sup>.

The range of virulence observed between *A. fischeri* strains (Figure 2) suggests that a categorical classification of non-pathogen may not apply equally well to all *A. fischeri* strains and that reliance on single reference strains is unreliable. Rather than classifying all *A. fischeri* strains "non-pathogenic" based on the pathogenic potential of a single reference strain, our results argue that we should instead evaluate the pathogenic potential of a diversity of strains. Capturing strain-to-strain variation in virulence (and other infection-related genetic and phenotypic traits) would enable us to more accurately describe the pathogenic potential of entire species. Applied to enough strains of multiple species, we may begin to see convergences or even overlaps in pathogenic potentials between species (Figure 6), blurring the distinction of pathogens and non-pathogens.

If *A. fischeri* exhibits such a range of heterogeneity in virulence, what explains its apparent absence in the clinic? We offer two not mutually exclusive explanations: lack of ecological opportunity and species misidentification. *A. fischeri* occupies similar ecological niches in natural environments as its close relative and major pathogen, *A. fumigatus*; the two species frequently co-occur in decaying matter and soil across a range of environments and latitudes<sup>31,59</sup>. However, while *Aspergillus* species are frequently isolated from hospital environments<sup>60-62</sup>, *A. fischeri* is less frequently present compared to more well-known *Aspergillus* pathogens, such as *A. fumigatus* or *A. flavus*<sup>63</sup>. If correct, this general absence of *A. fischeri* in clinical spaces would deny it the same ecological opportunity enjoyed by other more abundant species.

The second possible explanation for the absence of *A. fischeri* in the clinic lies in the challenge of accurately identifying fungal species. On the one hand, with ~150,000 species described from the likely millions of fungi inhabiting our planet<sup>64</sup>, we are continuously discovering new species, including new pathogens such as the emerging pathogen *Candida auris* (described in 2009) and the cryptic pathogen *Aspergillus lentulus* (described in 2005)<sup>7,65</sup>. On the other hand, accurate classification of fungal species is nontrivial and requires molecular barcodes<sup>66,67</sup>. Because accurate, species-level identification of infectious agents is rarely a priority in clinical settings (particularly in cases of opportunistic fungal infections), cryptic species are often undetected.

Such imprecisions in identification can inject biases into the literature. For example, species identification based upon isolate morphology led to misattribution of several cases of invasive aspergillosis to *A. fumigatus*, but subsequent examination of molecular barcodes implicated

another, morphologically indistinguishable, species in section *Fumigati*<sup>7</sup>. Indeed, an in-depth, metagenomic survey of four clinical environments revealed not only the pervasive co-occurrence of *A. fumigatus* and *A. fischeri*, but the relative proportions of the two species remained remarkably constant across environments (approximately 7:1)<sup>63</sup>. In contrast, clinical reports lean heavily on less-granular methods that are more expedient<sup>68</sup>. Moving forward, we argue that a more comprehensive picture of the pathogenic potential of fungal species must include both the accurate taxonomic attribution of clinical isolates, their relatives, and the distinction within species between more- and less-virulent strains. Along these lines, aided by advances in genome sequencing technologies, calls for the adoption of “taxogenomic” approaches to species identification, especially in biomedically relevant clades of fungi that are increasing<sup>69–71</sup>; implementation of such approaches would greatly increase our understanding of the species involved in fungal disease.

Variation in the pathogenic potentials of different strains then can be more deeply characterized, perhaps using moderate throughput *in vitro* assays (Figure 1), the results of which correspond well to the more-involved *in vivo* animal models of fungal disease (Figure 2). Metabolite profiling of these strains could then serve to examine how chemotypes evolve between/within species, possibly providing new insights into interplay between chemistry and pathogenic potential. Extension of this approach to strains in other species may reveal convergences in pathogenic potentials (Figure 6), providing not only evolutionary insights into how major pathogens originate, but also adding understanding to the underlying causes of virulence and effecting better clinical outcomes.

## METHODS

### ***A. fischeri* strains analyzed in this study**

All strains of *A. fischeri* were obtained from the culture collections of the Westerdijk Fungal Biodiversity Institute (Utrecht, The Netherlands). Strain identifiers and metadata are provided in Table 1.

### **Genome sequencing and quality assessment**

Each *A. fischeri* strain was grown at 30°C prior to DNA extraction. For long read sequencing, high molecular weight genomic DNA was isolated from pellets and sequenced by Oxford Nanopore (ONT) by SeqCenter (Pittsburgh, PA, USA). For short read DNA sequencing, genomic DNA was isolated using ZYMO RESEARCH Quick-DNA Fungal/Bacterial Kit, followed by TruSeq DNA PCR-Free library construction. Samples were then subject to 2 × 150 bp paired-end sequencing on an Illumina NovaSeq 6000 by VANTAGE NGS (Vanderbilt University, Nashville, TN, USA).

### ***De novo* genome assembly**

ONT reads from each strain were checked for contamination using Kaiju (v1.8.2)<sup>73</sup> and assembled using Flye (v.2.9-b1774)<sup>74</sup>. Long-read assemblies were polished with the Illumina reads using pilon (v1.24)<sup>75</sup>. The resulting assemblies were evaluated for completeness using BUSCO (fungi\_odb10 and eurotiomycetes\_odb10)<sup>76</sup>. Assembly parameters were optimized for each strain so as to maximize BUSCO completeness. Generally, optimal assemblies were obtained by thresholding Flye for a read error of 0.02, followed by 2 rounds of pilon polishing.

Assemblies were evaluated for quality using QUAST (QUality ASsessment Tool; v.5.2.0)<sup>77</sup> and the best assembly (DTO15) was chosen to serve as a reference genome for all the other strains. Contigs from the DTO15 assembly were then scaffolded against the telomere-to-telomere assembly of *A. fumigatus* CEA10<sup>78</sup>, retaining the chromosome numbering of the CEA10 strain.

## Gene annotation

Gene model prediction and functional annotation were performed for each strain using Funannotate<sup>79</sup> (v.1.5.14). Briefly, assemblies were masked for repetitive elements using RepeatMasker<sup>80</sup>. Transcript evidence for gene model training was obtained from the *de novo* assembly of RNAseq reads (see RNA sequencing section below) using Trinity<sup>81</sup>. Gene models predicted to encode peptides shorter than 50 amino acids or transposable elements were removed. Transfer-RNA prediction was performed using tRNAscan-SE<sup>82</sup>.

## Phylogenetics

To infer the strain phylogeny, single copy orthologs were extracted from the 16 *A. fischeri* genomes as well as two outgroup genomes of the *A. fumigatus* reference strains Af293<sup>83</sup> and CEA10<sup>78</sup> using BUSCO (v. 5.4.6)<sup>76</sup> and the eurotiomycetes\_odb10 data base (N=3,546 BUSCO entries). After filtering for BUSCO genes present across all strains and the outgroups (N=3,375, >96%), the remaining loci were aligned with Muscle5<sup>84</sup>. Manual inspection and curation identified 21 poorly identified and/or badly aligning sequences that were discarded. This process resulted in final multiple sequence alignments containing 3,354 genes, which were concatenated and used to build the strain phylogeny with IQ-TREE (v. 2.2.2.3)<sup>85</sup>.

## Pangenome analysis

The *A. fischeri* pangenome was constructed using Pantoools (v4.1.1)<sup>86,87</sup>. In short, a database was created using the amino acid sequences for each of the gene models produced by Funnanotate for each of the *A. fischeri* strains. Initial orthogroups were determined using the Pantoools' `build_panproteome` function, then the `optimal_grouping` function identified the optimal sequence similarity threshold (75%) for maximizing precision and recall (the F-score). Initial assessment of core, accessory, and singleton status of orthogroups was performed using the `gene_classification` function with default settings. The `gene_classification` function also provided a Heap's Law calculation.

Next, orthogroups from Pantoools were clustered by sequence similarity with a dynamic similarity threshold using ALFATClust (version available as of 04-10-2023) with default settings (Chiu & Ong 2022). This resulted in a set of 16,148 (16,427 including 279 multi-copy genes) gene clusters across all 16 strains. Each of these gene clusters were assigned a number within the parent orthogroup. Gene clusters were characterized as core, accessory, or singletons based on the number of strains represented in each cluster. Core genes were those gene clusters that contained sequences from all 16 strains, accessory genes contained sequences from 2-15 strains, and genes found in a single strain were considered singletons. Gene copy number was assessed by counting the number of sequences from each strain within a gene cluster. In downstream analysis, multicopy gene clusters (gene clusters that contained multiple genes from a single strain) and gene clusters whose average percent identity was lower than 70% were excluded from analysis.

To relate *A. fischeri* pangenomes back to the canonical reference strains of *A. fumigatus* (Af293) and *A. fischeri* (NRRL 181), we sourced annotations for Af293 and NRRL181 from FungiDB release 62<sup>88</sup>. These reference sequences were used to construct a custom BLAST database against which, pangenecluster centroids (identified using DIAMOND (v2.1.6)<sup>89</sup>) were reciprocally BLASTed. Any duplicate BLAST results were resolved by selecting for maximum bit score. The homologous genes found were used for annotating the pangenome.

## Population genetics

Population genetic analyses were performed with GATK (v. 4.1.2.0-Java-1.8.0\_192)<sup>90</sup>. DTO15 was designated the reference genome, which was indexed using SAMtools (v. 1.16.1)<sup>91</sup>, BWA (v 0.7.17)<sup>92</sup>, and GATK. To produce a high-confidence SNV set (known\_sites file), we initially ran GATK in default diploid mode applying quality filtering with VCFtools (v. 0.1.16)<sup>93</sup> and the following flags: --minGQ 20, --minDP 5, -min-meanDP 10, --mac 3 to the preliminary population VCF file. We extracted the resulting genotype table and used sed to remove all heterozygous SNVs. This set of high-confidence SNVs became the known\_sites file. We then performed the analysis following the "Germline short variant discovery (SNVs + Indels)" best practices (<https://gatk.broadinstitute.org/hc/en-us/articles/360035535932-Germline-short-variant-discovery-SNVs-Indels->). Duplicates were marked, base quality score recalibration (BQSR) was performed with the custom known\_sites file, and SNVs were called with GATK's HaplotypeCallerSpark, setting sample-ploidy to 1; a total of 303,690 SNVs were identified. Applying the traditional/alternative hard filtering<sup>94</sup> did not remove any SNVs.

To infer population structure, we used ADMIXTURE (v1.3.0)<sup>95</sup> on the set of 303,690 SNVs.

These SNVs were first filtered on allele frequency using *vcftools*<sup>93</sup> (resulting in 215,627 SNVs with an allele frequency greater than 10%), LD pruned in PLINK<sup>96</sup>, then clustered by PCA to create input for ADMIXTURE. Finally, ADMIXTURE was run using both 5- and 10- fold cross validation and K values were selected based upon local minima of cross validation errors.

### **Biosynthetic Gene Cluster detection**

To identify biosynthetic gene clusters (BGCs), we collected the genes and locus tags from primary literature and the BGC repository MIBiG (v3.1)<sup>97</sup>. BGCs in the *A. fischeri* strains were annotated by antiSMASH (v6.0.1)<sup>98</sup> and manually reviewed to confirm gene content, borders and syntenic similarity.

### **RNAseq sample preparation and RNA isolation**

For RNAseq preparation, conidial suspensions from 15 strains were harvested from 3 days old-conidia cultured on complete media (strain DTO7 was excluded because of poor growth at 37°C). The conidial suspension was counted using a hemocytometer and adjusted to a final concentration of  $1 \times 10^8$  conidia/ml. For the two experimental conditions, conidia were cultured in 250 mL flasks containing 30 mL minimal media and incubated at either 30°C or 37°C for 24 hours with agitation.

For RNA extraction, material was pelleted by centrifugation, the pellet separated by filtration, rinsed with water, flash frozen, and stored at -80°C. For total RNA extraction, the mycelial biomass (around 100 mg of tissue) was first homogenized by grinding in liquid nitrogen and then

RNA was isolated using TRIzol (Invitrogen, Catalog Number 15596026) and cleaned up with the RNeasy clean-up method (Qiagen, Catalog Number 74104). Finally, the RNA extract was treated using DNase (Qiagen cat#79254) and was quantified using a spectrophotometer. The purified RNA was stored at -80°C.

### **RNA sequencing**

RNA samples submitted to Vanderbilt's sequencing center VANTAGE NGS (Vanderbilt University, Nashville, TN, USA), where RNA was again checked for RNA integrity poly-A enriched prior to Illumina preparation using NEBNext® Poly(A) selection followed by paired-end sequencing (150bp from each end) on an Illumina NovaSeq 6000 S4.

### **RNAseq read alignment and differential expression**

Reads were quality checked using FastQC (v0.11.9)<sup>99</sup> and filtered using Trimmomatic (v0.040-rc1)<sup>100</sup>. Reads from each strain were aligned back to that strain's genome assembly and unique set of gene models using STAR (v2.7.10b)<sup>101</sup>. Unique read counts per strain were then gathered for each sample using HTseq (v.2.0.3)<sup>102</sup>. Counts were then evaluated on a strain-by-strain basis for differential expression between the 30°C and 37°C treatment groups (three replicates per treatment using DEseq2 (v1.42.0)<sup>103</sup>. DEseq2 gene names were standardized across all samples using the pangenome results. Genes were considered to be significantly differentially expressed if their false discovery rate-corrected (Benjamini and Hochberg method) p-value (padj) was less than 0.05.

### **Growth and extraction of *Aspergillus fischeri* cultures for chemical analyses**

*A. fischeri* strains (n=16) were grown in oatmeal cereal media (Old fashioned breakfast Quaker oats) for chemical characterization <sup>29</sup>. Briefly, fungal cultures were started by aseptically cutting mycelia from a culture growing in a Petri dish on malt extract agar (MEA, Difco), and this material was transferred to a sterile Falcon tube with 10 mL of liquid YESD media (YESD; 20 g soy peptone, 20 g dextrose, 5 g yeast extract, 1 L distilled H<sub>2</sub>O). This seed culture was grown for 7 days on an orbital shaker (~100 rpm) at room temperature (~23°C) and used to inoculate the oatmeal cereal media, which was prepared by adding 10 g of oatmeal in a 250 mL, wide mouth Erlenmeyer flask with ~17 mL of deionized water followed by autoclaving at 121°C for 30 min. For each of the 16 strains, three flasks of each of the samples (i.e., three biological replicates per sample) were incubated for 10 d at 30°C and three at 37°C. Since it is known that light modulates growth, sexual reproduction, and secondary metabolite production in fungi <sup>104</sup>, the incubators were equipped with LED lamps (Ustellar, flexible LED strip lights; 24 W) with light regulated into 12:12 h dark/light cycles <sup>105</sup>.

At the end of 10 d, each individual flask was extracted by adding 60 mL of CHCl<sub>3</sub>-MeOH (1:1), chopped with a spatula, and shaken overnight (~16 h) at ~100 rpm at room temperature. The cultures were then filtered *in vacuo*, and 90 mL of CHCl<sub>3</sub> and 150 mL of deionized water were added to each of the filtrates. The mixture was then transferred to a separatory funnel and shaken vigorously. The organic layer (*i.e.*, bottom layer) was drawn off and evaporated to dryness *in vacuo*. The dried organic layer was reconstituted in a 100 mL of CH<sub>3</sub>CN-MeOH (1:1) and 100 mL of hexanes, transferred to a separatory funnel, and shaken vigorously. The defatted organic layers were evaporated to dryness.

All the defatted organic layers were analyzed individually by UPLC-HRESI-MS utilizing a Thermo LTQ Orbitrap XL mass spectrometer equipped with an electrospray ionization source. A Waters Acquity UPLC was utilized with a BEH C18 column (1.7  $\mu$ m; 50 mm  $\times$  2.1 mm) set to 40°C and a flow rate of 0.3 mL/min. The mobile phase consisted of a linear gradient of CH<sub>3</sub>CN–H<sub>2</sub>O (both acidified with 0.1% formic acid), starting at 15% CH<sub>3</sub>CN and increasing linearly to 100% CH<sub>3</sub>CN over 8 min, with a 1.5 min hold before returning to the starting conditions. The profile of secondary metabolites of all the extracts was examined using well-established procedures <sup>29</sup>.

### **Isolation and identification of secondary metabolites**

After comparison of the UPLC-HRESI-MS data for each biological replicate, the defatted organic layers for each strain and condition were combined due to the similarity of their chemical profiles, so as to generate a larger pool of material for isolation studies, which were carried out using well-established natural products chemistry procedures <sup>106,107</sup>. The extracts were first fractionated by normal phase flash chromatography, and the fungal metabolites were isolated using preparative HPLC.

The isolated fungal metabolites were identified by direct comparison of the spectroscopic and spectrometric properties with those reported previously, and where possible, structures were validated by comparisons with authentic reference standards <sup>107</sup>. Additionally, mass defect filtering<sup>108</sup> was used to identify structurally-related analogues of the isolated compounds.

The NMR data were collected using a JEOL ECS-400 spectrometer operating at 400 MHz for <sup>1</sup>H and 100 MHz for <sup>13</sup>C, an JEOL ECA-500 spectrometer operating at 500 MHz for <sup>1</sup>H and 125 MHz for <sup>13</sup>C or an Agilent 700 MHz spectrometer, equipped with a cryoprobe, operating at 700 MHz for <sup>1</sup>H and 175 MHz for <sup>13</sup>C. The HPLC separations were performed on a Varian Prostar HPLC system equipped with a Prostar 210 pump and a Prostar 335 photodiode array detector (PDA), with the collection and analysis of data using Galaxy Chromatography Workstation software. The columns used for separations were either a Synergi C18 preparative (4  $\mu$ m; 21.2  $\times$  250 mm) column at a flow rate of 21.2 mL/min, Luna PFP(2) preparative (5  $\mu$ m; 21.2  $\times$  250 mm) column at a flow rate of 17 mL/min or an Gemini NX-C18 preparative (5  $\mu$ m; 19  $\times$  250 mm) column at a flow rate of 17 mL/min. Flash chromatography was performed on a Teledyne ISCO Combiflash Rf 200 and monitored by ELSD and PDA detectors.

### **Principal component analysis of metabolomics results**

Principal component analysis (PCA) and hierarchical clustering were performed on the UPLC-HRESI-MS data. Untargeted UPLC-HRESI-MS datasets for each sample were individually aligned, filtered, and analyzed using Mzmine (v2.53) (<https://sourceforge.net/projects/mzmine/>). Peak list filtering and retention time alignment algorithms were used to refine peak detection, and the join algorithm integrated all sample profiles into a data matrix using the following parameters: Mass detection: MS1 positive mode. ADAP: Group intensity threshold: 20000, Min highest intensity: 60000, m/z tolerance: 0.003. Chromatogram deconvolution: Wavelets (ADAP) algorithm. Join aligner and gap filling: retention time tolerance: 0.05 min, m/z tolerance: 0.0015 m/z. The resulting data matrix was exported to Excel (Microsoft) for analysis as a set of m/z-RT (retention time) pairs with individual peak areas. Samples that did not possess detectable

quantities of a given marker ion were assigned a peak area of zero to maintain the same number of variables for all sample sets. Ions that did not elute between 1 and 10 min and/or had an m/z ratio < 200 or > 900 Da were removed from analysis. Relative standard deviation was used to understand the quantity of variance between the injections, which may differ slightly based on instrument variance. A cutoff of 1.0 was used at any given m/z-RT pair across the biological replicate injections, and if the variance was greater than the cutoff, it was assigned a peak area of zero. PCA analysis and hierarchical clustering were created with Python. The PCA scores plots were generated using the averaged data of the three individual biological replicates.

### **Murine model of pulmonary aspergillosis**

Wild-type BALB/c female mice, body weight 20 to 22 g, aged 8-9 weeks, were kept in the Animal Facility of the Laboratory of Molecular Biology of the School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo (FCFRP/USP), in a clean and silent environment, under normal conditions of humidity and temperature, and with a 12:12 h dark/light cycle. The mice were given food and water ad libitum throughout the experiments. Mice were immunosuppressed with cyclophosphamide (150 mg per kg of body weight), which was administered intraperitoneally on days -4, -1, and 2 prior to and post infection. Hydrocortisonacetate (200mg/ kg body weight) was injected subcutaneously on day -3. *A. fischeri* strains and the *A. fumigatus* CEA17 strain, a clinically derived and highly virulent strain, that we used as a positive control, were grown on minimal media for 2 days prior to infection. Fresh conidia were harvested in PBS and filtered through a Miracloth (Calbiochem). Conidial suspensions were spun for 5 min at 3,000 x g, washed three times with PBS, counted using a hemocytometer, and resuspended at a concentration of 5.0 x 10<sup>6</sup> conidia/ ml. The viability of the

administered inoculum was determined by incubating a serial dilution of the conidia on minimal media at 37°C. Mice were anesthetized by halothane inhalation and infected by intranasal instillation of 1.0 x 10<sup>5</sup> conidia in 20 µl of PBS. As a negative control, a group of 10 mice received PBS only. Mice were weighed every 24 h from the day of infection and visually inspected twice daily. The statistical significance of comparative survival values was calculated by Prism statistical analysis package by using the Log-rank (Mantel-Cox) Test and Gehan-Breslow-Wilcoxon tests.

The virulence of each strain of *A. fischeri* was evaluated in cohorts of 20 mice (10 treatments, 10 negative PBS controls). A positive control cohort of 20 mice was also evaluated (10 *A. fumigatus* CEA17 treatments and 10 negative PBS controls). Two replicates of each cohort were conducted.

The principles that guide our studies are based on the Declaration of Animal Rights ratified by UNESCO on January 27, 1978 in its 8th and 14th articles. All protocols adopted in this study were approved by the local ethics committee for animal experiments from the University of São Paulo, Campus of Ribeirão Preto (Permit Number: 08.1.1277.53.6; Studies on the interaction of *A. fischeri* with animals). Groups of five animals were housed in individually ventilated cages and were cared for in strict accordance with the principles outlined by the Brazilian College of Animal Experimentation (COBEA) and Guiding Principles for Research Involving Animals and Human Beings, American Physiological Society. All efforts were made to minimize suffering. Animals were clinically monitored at least twice daily and humanely sacrificed if moribund

(defined by lethargy, dyspnea, hypothermia, and weight loss). All stressed animals were sacrificed by cervical dislocation.

### **Macrophage cytokine response to conidia**

*Aspergillus* strains were cultivated on minimal medium agar plates at 37°C for 3 days. Conidia were harvested in sterile water with 0.05 % (vol/vol) Tween20. The resulting suspension was filtered through two layers of gauze (Miracloth, Calbiochem). The conidial concentration was determined using a hemocytometer.

BALB/c bone marrow-derived macrophages (BMDMs) were obtained as previously described<sup>109</sup>. Briefly, bone marrow cells were cultured for 7–9 days in RPMI 20/30, which consists of RPMI-1640 medium (Gibco, Thermo Fisher Scientific Inc.), supplemented with 20 % (vol/ vol) FBS and 30 % (vol/vol) L-Cell Conditioned Media (LCCM) as a source of macrophage colony-stimulating factor (M-CSF) on non-treated Petri dishes (Optilux - Costar, Corning Inc. Corning, NY). Twenty-four hours before experiments, BMDM monolayers were detached using cold phosphate-buffered saline (PBS) (Hyclone, GE Healthcare Inc. South Logan, UT) and cultured, as specified, in RPMI-1640 (Gibco, Thermo Fisher Scientific Inc.) supplemented with 10 % (vol/vol) FBS, 10 U/mL penicillin, and 10 mg/mL streptomycin, (2 mM) L-glutamine, (25 mM) HEPES, pH 7.2 (Gibco, Thermo Fisher Scientific Inc.) at 37°C in 5 % (vol/vol) CO<sub>2</sub> for the indicated periods.

BMDMs were seeded at a density of 10<sup>6</sup> cells/ml in 24-well plates (Greiner Bio-One, Kremsmünster, Austria). The cells were challenged with the conidia of different strains at a multiplicity of infection of 1:10 and incubated at 37°C with 5 % (vol/vol) CO<sub>2</sub> for 48h. BMDMs

were also stimulated with lipopolysaccharide (LPS; standard LPS, *E. coli* 0111: B4; Sigma-Aldrich, 500 ng/mL) plus Nigericin (tlrl-nig, InvivoGen 5  $\mu$ M/mL) and cell medium alone, which were used respectively as the positive and negative controls. Cell culture supernatants were collected and stored at  $-80^{\circ}\text{C}$  until they were assayed for TNF- $\alpha$ , IL-1, and IL-6 release using Mouse DuoSet ELISA kits (R&D Systems, Minneapolis, MN, USA, according to the manufacturer's instructions. For cytokine determination, plates were analyzed by using a microplate reader (Synergy<sup>TM</sup> HTX Multi-Mode, BioTek) measuring absorbance at 450 nm. Cytokine concentrations were interpolated from a standard curve and statistical significance was determined using an ANOVA.

### **Macrophage killing assay**

BMDMs were seeded at a density of  $10^6$  cells/ml in 24-well plates (Corning<sup>®</sup> Costar<sup>®</sup>) and were challenged with conidia at a multiplicity of infection of 1:10 and incubated a  $37^{\circ}\text{C}$  with 5 % (vol/vol)  $\text{CO}_2$  for 24h. After incubation media was removed the cells were washed with ice-cold PBS and finally 2 ml of sterile water was added to the wells. A P1000 tip was then used to scrape away the cell monolayer and the cell suspension was collected. This suspension was then diluted 1:1000 and 100  $\mu\text{l}$  was plated on Sabouraud agar before the plates were incubated at  $37^{\circ}\text{C}$  overnight and the colonies were counted. 50  $\mu\text{l}$  of the inoculum adjusted to  $10^3/\text{ml}$  was also plated on SAB agar to correct CFU counts. The CFU/ml for each sample was calculated and compared to the A1160 wild-type strain using (GraphPad Prism 8.0, La Jolla, CA). All assays were performed in four replicates in two independent experiments.

## Growth phenotyping

All strains were cultured from conidial glycerol stock (stored at -80°C) on Complete Minimal media agar plates (20 g of D-glucose, 50 mL of 20x salt solution [120 g of NaNO<sub>3</sub>, 10.4 g of KCl, 10.4 g of MgSO<sub>4</sub> x 7H<sub>2</sub>O and 30.4 g of KH<sub>2</sub>PO<sub>4</sub> g/L], 1 mL Trace Element Solution [22 g of ZnSO<sub>4</sub> x7H<sub>2</sub>O, 11 g of H<sub>3</sub>BO<sub>3</sub>, 5 g of MnCl<sub>2</sub>x4H<sub>2</sub>O, 5 g of FeSO<sub>4</sub>x7H<sub>2</sub>O, 1.6 g of COCl<sub>2</sub>x 5H<sub>2</sub>O, 1.6 g of CuSO<sub>4</sub> x5H<sub>2</sub>O, 1.1 g of (NH<sub>4</sub>)<sub>6</sub>Mo<sub>7</sub>O<sub>24</sub>x4H<sub>2</sub>O, and 50 g of Na<sub>4</sub>EDTA], 1 g of Yeast Extract, 2 g of Peptone, and 1.5 g of Casamino Acid g/L, 1.5% of agar, pH adjusted to 6.5) at 30°C under dark conditions in a culture chamber (Thermo Fisher, MaxQ6000). A 6 mm cork borer was used to obtain edge mycelia and subculture on Minimal Media Agar (50 mL 20x solution, 1 mL Trace Solution, and 10 g of D-glucose, 20% of agar and adjusted pH at 6.5) at 30°C and 37°C under dark conditions. After 2 days of growth, the radial growth of the mycelial mats for each strain was quantified manually using a ruler. Three replicates were done per strain, per temperature condition.

## DATA AVAILABILITY

Sequencing data and genome assemblies associated with this project will become available through GenBank upon publication. The NMR data will be deposited in the Natural Products Magnetic Resonance Database (<https://npmrdb-project.org/>). All other data necessary to replicate this work will be available on FigShare.

## ACKNOWLEDGMENTS

We thank members of the Rokas lab for helpful discussions and feedback. Computational infrastructure at Vanderbilt University was provided by The Advanced Computing Center for Research and Education (ACCRE). This research was supported by the National Institutes of Health National Institute of Allergy and Infectious Diseases (R01 AI153356). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Research in A.R.'s lab is also supported by the National Science Foundation (DEB-2110404) and the Burroughs Wellcome Fund. Research in G.H.G.'s lab is also supported by the Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) grant numbers 2021/04977-5 (G.H.G.) and 2023/00206-0 (ED), the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) grant numbers 301058/2019-9 and 404735/2018-5 (G.H.G.), and the CNPq, FAPESP and Fundação Coordenação de Aperfeiçoamento do Pessoal do Ensino Superior (CAPES) grant number 405934/2022-0 to G.H.G. (The National Institute of Science and Technology INCT Funvir), all from Brazil. G.H.G.'s lab was also funded by the Joint Canada-Israel Health Research Program, jointly supported by the Azrieli Foundation, Canada's International Development Research Centre, Canadian Institutes of Health Research, and the Israel Science Foundation. This work was performed in part at the Joint School of Nanoscience and Nanoengineering, a member of the National Nanotechnology Coordinated Infrastructure (NNCI), which is supported by the National Science Foundation (NSF; Grant ECCS-2025462).

## **CONFLICT OF INTEREST**

A. R. is a scientific consultant for LifeMine Therapeutics, Inc.

## REFERENCES

1. Drgona, L., Khachatrian, A., Stephens, J., Charbonneau, C., Kantecki, M., Haider, S. & Barnes, R. Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of Aspergillus and Candida species. *Eur. J. Clin. Microbiol. Infect. Dis.* **33**, 7–21 (2014).
2. Vallabhaneni, S., Mody, R. K., Walker, T. & Chiller, T. The Global Burden of Fungal Diseases. *Infect. Dis. Clin. North Am.* **30**, 1–11 (2016).
3. Benedict, K., Jackson, B. R., Chiller, T. & Beer, K. D. Estimation of Direct Healthcare Costs of Fungal Diseases in the United States. *Clin. Infect. Dis.* **68**, 1791–1797 (2019).
4. Denning, D. W. Global incidence and mortality of severe fungal disease. *Lancet Infect. Dis.* (2024). doi:10.1016/S1473-3099(23)00692-8
5. Bongomin, F., Gago, S., Oladele, R. O. & Denning, D. W. Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision. *J Fungi (Basel)* **3**, (2017).
6. Lamothe, F. Aspergillus fumigatus-Related Species in Clinical Practice. *Front. Microbiol.* **7**, 683 (2016).
7. Balajee, S. A., Kano, R., Baddley, J. W., Moser, S. A., Marr, K. A., Alexander, B. D., Andes, D., Kontoyiannis, D. P., Perrone, G., Peterson, S., Brandt, M. E., Pappas, P. G. & Chiller, T. Molecular identification of Aspergillus species collected for the Transplant-Associated Infection Surveillance Network. *J. Clin. Microbiol.* **47**, 3138–3141 (2009).
8. Alastruey-Izquierdo, A., Mellado, E., Peláez, T., Pemán, J., Zapico, S., Alvarez, M., Rodríguez-Tudela, J. L., Cuenca-Estrella, M. & FILPOP Study Group. Population-based survey of filamentous fungi and antifungal resistance in Spain (FILPOP Study). *Antimicrob. Agents Chemother.* **57**, 3380–3387 (2013).

9. van der Linden, J. W. M., Arendrup, M. C., Warris, A., Lagrou, K., Pelloux, H., Hauser, P., M., Chryssanthou, E., Mellado, E., Kidd, S. E., Tortorano, A. M., Dannaoui, E., Gaustad, P., Baddley, J. W., Uekötter, A., Lass-Flörl, C., Klimko, N., Moore, C. B., Denning, D. W., Pasqualotto, A. C., Kibbler, C., Arikan-Akdagli, S., Andes, D., Meletiadis, J., Naumiuk, L., Nucci, M., Melchers, W. J. G. & Verweij, P. E. Prospective multicenter international surveillance of azole resistance in *Aspergillus fumigatus*. *Emerg. Infect. Dis.* **21**, 1041–1044 (2015).
10. Steenwyk, J. L., Rokas, A. & Goldman, G. H. Know the enemy and know yourself: Addressing cryptic fungal pathogens of humans and beyond. *PLoS Pathog.* **19**, e1011704 (2023).
11. Latgé, J.-P. & Chamilos, G. *Aspergillus fumigatus* and Aspergillosis in 2019. *Clin. Microbiol. Rev.* **33**, (2019).
12. Casadevall, A. & Pirofski, L.-A. Accidental virulence, cryptic pathogenesis, martians, lost hosts, and the pathogenicity of environmental microbes. *Eukaryot. Cell* **6**, 2169–2174 (2007).
13. Rokas, A. Evolution of the human pathogenic lifestyle in fungi. *Nature Microbiology* **7**, 607–619 (2022).
14. Ackermann, M. A functional perspective on phenotypic heterogeneity in microorganisms. *Nat. Rev. Microbiol.* **13**, 497–508 (2015).
15. Barber, A. E., Sae-Ong, T., Kang, K., Seelbinder, B., Li, J., Walther, G., Panagiotou, G. & Kurzai, O. *Aspergillus fumigatus* pan-genome analysis identifies genetic variants associated with human infection. *Nat Microbiol* **6**, 1526–1536 (2021).
16. Colabardini, A. C., Wang, F., Miao, Z., Pardeshi, L., Valero, C., de Castro, P. A., Akiyama,

D. Y., Tan, K., Nora, L. C., Silva-Rocha, R., Marcet-Houben, M., Gabaldón, T., Fill, T., Wong, K. H. & Goldman, G. H. Chromatin profiling reveals heterogeneity in clinical isolates of the human pathogen *Aspergillus fumigatus*. *PLoS Genet.* **18**, e1010001 (2022).

17. Kowalski, C. H., Beattie, S. R., Fuller, K. K., McGurk, E. A., Tang, Y.-W., Hohl, T. M., Obar, J. J. & Cramer, R. A., Jr. Heterogeneity among Isolates Reveals that Fitness in Low Oxygen Correlates with *Aspergillus fumigatus* Virulence. *MBio* **7**, (2016).

18. Kowalski, C. H., Kerkaert, J. D., Liu, K.-W., Bond, M. C., Hartmann, R., Nadell, C. D., Stajich, J. E. & Cramer, R. A. Fungal biofilm morphology impacts hypoxia fitness and disease progression. *Nat Microbiol* **4**, 2430–2441 (2019).

19. Fuller, K. K., Cramer, R. A., Zegans, M. E., Dunlap, J. C. & Loros, J. J. *Aspergillus fumigatus* Photobiology Illuminates the Marked Heterogeneity between Isolates. *MBio* **7**, (2016).

20. Steenwyk, J. L., Mead, M. E., Knowles, S. L., Raja, H. A., Roberts, C. D., Bader, O., Houbreken, J., Goldman, G. H., Oberlies, N. H. & Rokas, A. Variation Among Biosynthetic Gene Clusters, Secondary Metabolite Profiles, and Cards of Virulence Across *Aspergillus* Species. *Genetics* **216**, 481–497 (2020).

21. Lind, A. L., Wisecaver, J. H., Lameiras, C., Wiemann, P., Palmer, J. M., Keller, N. P., Rodrigues, F., Goldman, G. H. & Rokas, A. Drivers of genetic diversity in secondary metabolic gene clusters within a fungal species. *PLoS Biol.* **15**, e2003583 (2017).

22. Hagiwara, D., Takahashi, H., Takagi, H., Watanabe, A. & Kamei, K. Heterogeneity in Pathogenicity-related Properties and Stress Tolerance in *Aspergillus fumigatus* Clinical Isolates. *Med. Mycol. J.* **59**, E63–E70 (2018).

23. Altamirano, S., Jackson, K. M. & Nielsen, K. The interplay of phenotype and genotype in

Cryptococcus neoformans disease. *Biosci. Rep.* **40**, (2020).

24. Badrane, H., Cheng, S., Dupont, C. L., Hao, B., Driscoll, E., Morder, K., Liu, G., Newbrough, A., Fleres, G., Kaul, D., Espinoza, J. L., Clancy, C. J. & Nguyen, M. H. Genotypic diversity and unrecognized antifungal resistance among populations of *Candida glabrata* from positive blood cultures. *Nat. Commun.* **14**, 5918 (2023).

25. Dumeaux, V., Massahi, S., Bettauer, V., Mottola, A., Dukovny, A., Khurdia, S. S., Costa, A. C. B. P., Omran, R. P., Simpson, S., Xie, J. L., Whiteway, M., Berman, J. & Hallett, M. T. *Candida albicans* exhibits heterogeneous and adaptive cytoprotective responses to antifungal compounds. *Elife* **12**, (2023).

26. Ries, L. N. A., Steenwyk, J. L., de Castro, P. A., de Lima, P. B. A., Almeida, F., de Assis, L. J., Manfiolli, A. O., Takahashi-Nakaguchi, A., Kusuya, Y., Hagiwara, D., Takahashi, H., Wang, X., Obar, J. J., Rokas, A. & Goldman, G. H. Nutritional Heterogeneity Among *Aspergillus fumigatus* Strains Has Consequences for Virulence in a Strain- and Host-Dependent Manner. *Front. Microbiol.* **10**, 854 (2019).

27. Sauters, T. J. C., Roth, C., Murray, D., Sun, S., Floyd Averette, A., Onyishi, C. U., May, R. C., Heitman, J. & Magwene, P. M. Amoeba predation of *Cryptococcus*: A quantitative and population genomic evaluation of the accidental pathogen hypothesis. *PLoS Pathog.* **19**, e1011763 (2023).

28. Colabardini, A. C., Wang, F., Dong, Z., Pardeshi, L., Rocha, M. C., Costa, J. H., Dos Reis, T. F., Brown, A., Jaber, Q. Z., Fridman, M., Fill, T., Rokas, A., Malavazi, I., Wong, K. H. & Goldman, G. H. Heterogeneity in the transcriptional response of the human pathogen *Aspergillus fumigatus* to the antifungal agent caspofungin. *Genetics* **220**, (2022).

29. Mead, M. E., Knowles, S. L., Raja, H. A., Beattie, S. R., Kowalski, C. H., Steenwyk, J. L.,

Silva, L. P., Chiaratto, J., Ries, L. N. A., Goldman, G. H., Cramer, R. A., Oberlies, N. H. & Rokas, A. Characterizing the Pathogenic, Genomic, and Chemical Traits of *Aspergillus fischeri*, a Close Relative of the Major Human Fungal Pathogen *Aspergillus fumigatus*. *mSphere* **4**, (2019).

30. Houbraken, J., Weig, M., Groß, U., Meijer, M. & Bader, O. *Aspergillus oerlinghausensis*, a new mould species closely related to *A. fumigatus*. *FEMS Microbiol. Lett.* **363**, (2016).

31. Klich, M. A. Biogeography of *Aspergillus* species in soil and litter. *Mycologia* **94**, 21–27 (2002).

32. Evelyn & Silva, F. V. M. Modeling the inactivation of *Neosartorya fischeri* ascospores in apple juice by high pressure, power ultrasound and thermal processing. *Food Control* **59**, 530–537 (2016).

33. Pitt, J. I. & Hocking, A. D. *Fungi and Food Spoilage*. (Springer US, 2009).

34. Kavanagh, J., Larchet, N. & Stuart, M. Occurrence of a Heat-resistant Species of *Aspergillus* in Canned Strawberries. *Nature* **198**, 1322–1322 (1963).

35. Summerbell, R. C., de Repentigny, L., Chartrand, C. & St Germain, G. Graft-related endocarditis caused by *Neosartorya fischeri* var. *spinosa*. *J. Clin. Microbiol.* **30**, 1580–1582 (1992).

36. Lonial, S., Williams, L., Carrum, G., Ostrowski, M. & McCarthy, P., Jr. *Neosartorya fischeri*: an invasive fungal pathogen in an allogeneic bone marrow transplant patient. *Bone Marrow Transplant.* **19**, 753–755 (1997).

37. Gerber, J., Chomicki, J., Brandsberg, J. W., Jones, R. & Hammerman, K. J. Pulmonary aspergillosis caused by *Aspergillus fischeri* var. *spinosa*: report of a case and value of serologic studies. *Am. J. Clin. Pathol.* **60**, 861–866 (1973).

38. Coriglione, G., Stella, G., Gafa, L., Spata, G., Oliveri, S., Padhye, A. A. & Ajello, L. *Neosartorya fischeri* var *fischeri* (Wehmer) Malloch and Cain 1972 (anamorph: *Aspergillus fischerianus* Samson and Gams 1985) as a cause of mycotic keratitis. *Eur. J. Epidemiol.* **6**, 382–385 (1990).
39. Chim, C. S., Ho, P. L. & Yuen, K. Y. Simultaneous *Aspergillus fischeri* and *Herpes simplex* pneumonia in a patient with multiple myeloma. *Scand. J. Infect. Dis.* **30**, 190–191 (1998).
40. Gori, S., Pellegrini, G., Filipponi, F., Della Capanna, S., Biancofiore, G. L., Mosca, F., Lofaro, A. & Others. Pulmonary aspergillosis caused by *Neosartorya fischeri* (*Aspergillus fischerianus*) in a liver transplant recipient. *J. Mycol. Med.*
41. Bertuzzi, M., van Rhijn, N., Krappmann, S., Bowyer, P., Bromley, M. J. & Bignell, E. M. On the lineage of *Aspergillus fumigatus* isolates in common laboratory use. *Med. Mycol.* **59**, 7–13 (2021).
42. Kjærboølling, I., Vesth, T. C., Frisvad, J. C., Nybo, J. L., Theobald, S., Kuo, A., Bowyer, P., Matsuda, Y., Mondo, S., Lyhne, E. K., Kogle, M. E., Clum, A., Lipzen, A., Salamov, A., Ngan, C. Y., Daum, C., Chiniquy, J., Barry, K., LaButti, K., Haridas, S., Simmons, B. A., Magnuson, J. K., Mortensen, U. H., Larsen, T. O., Grigoriev, I. V., Baker, S. E. & Andersen, M. R. Linking secondary metabolites to gene clusters through genome sequencing of six diverse *Aspergillus* species. *Proc. Natl. Acad. Sci. U. S. A.* **115**, E753–E761 (2018).
43. Abad, A., Fernández-Molina, J. V., Bikandi, J., Ramírez, A., Margareto, J., Sendino, J., Hernando, F. L., Pontón, J., Garaizar, J. & Rementeria, A. What makes *Aspergillus fumigatus* a successful pathogen? Genes and molecules involved in invasive aspergillosis. *Rev. Iberoam. Micol.* **27**, 155–182 (2010).

44. Raffa, N. & Keller, N. P. A call to arms: Mustering secondary metabolites for success and survival of an opportunistic pathogen. *PLoS Pathog.* **15**, e1007606 (2019).
45. Bignell, E., Cairns, T. C., Throckmorton, K., Nierman, W. C. & Keller, N. P. Secondary metabolite arsenal of an opportunistic pathogenic fungus. *Philos. Trans. R. Soc. Lond. B Biol. Sci.* **371**, (2016).
46. Steenwyk, J. L., Mead, M. E., de Castro, P. A., Valero, C., Damasio, A., Dos Santos, R. A. C., Labella, A. L., Li, Y., Knowles, S. L., Raja, H. A., Oberlies, N. H., Zhou, X., Cornely, O. A., Fuchs, F., Koehler, P., Goldman, G. H. & Rokas, A. Genomic and Phenotypic Analysis of COVID-19-Associated Pulmonary Aspergillosis Isolates of *Aspergillus fumigatus*. *Microbiol Spectr* **9**, e0001021 (2021).
47. Wiemann, P., Lechner, B. E., Baccile, J. A., Velk, T. A., Yin, W.-B., Bok, J. W., Pakala, S., Losada, L., Nierman, W. C., Schroeder, F. C., Haas, H. & Keller, N. P. Perturbations in small molecule synthesis uncovers an iron-responsive secondary metabolite network in *Aspergillus fumigatus*. *Front. Microbiol.* **5**, 530 (2014).
48. Steenwyk, J. L., Lind, A. L., Ries, L. N. A., Dos Reis, T. F., Silva, L. P., Almeida, F., Bastos, R. W., Fraga da Silva, T. F. de C., Bonato, V. L. D., Pessoni, A. M., Rodrigues, F., Raja, H. A., Knowles, S. L., Oberlies, N. H., Lagrou, K., Goldman, G. H. & Rokas, A. Pathogenic Allodiploid Hybrids of *Aspergillus* Fungi. *Curr. Biol.* **30**, 2495–2507.e7 (2020).
49. Drott, M. T., Bastos, R. W., Rokas, A., Ries, L. N. A., Gabaldón, T., Goldman, G. H., Keller, N. P. & Greco, C. Diversity of Secondary Metabolism in *Aspergillus nidulans* Clinical Isolates. *mSphere* **5**, (2020).
50. Romani, L. Immunity to fungal infections. *Nat. Rev. Immunol.* **11**, 275–288 (2011).
51. Casadevall, A. & Pirofski, L. A. Host-pathogen interactions: redefining the basic concepts

of virulence and pathogenicity. *Infect. Immun.* **67**, 3703–3713 (1999).

52. Yin, W.-B., Baccile, J. A., Bok, J. W., Chen, Y., Keller, N. P. & Schroeder, F. C. A nonribosomal peptide synthetase-derived iron(III) complex from the pathogenic fungus *Aspergillus fumigatus*. *J. Am. Chem. Soc.* **135**, 2064–2067 (2013).

53. Spikes, S., Xu, R., Nguyen, C. K., Chamilos, G., Kontoyiannis, D. P., Jacobson, R. H., Ejzykowicz, D. E., Chiang, L. Y., Filler, S. G. & May, G. S. Gliotoxin production in *Aspergillus fumigatus* contributes to host-specific differences in virulence. *J. Infect. Dis.* **197**, 479–486 (2008).

54. Misslinger, M., Hortschansky, P., Brakhage, A. A. & Haas, H. Fungal iron homeostasis with a focus on *Aspergillus fumigatus*. *Biochim. Biophys. Acta Mol. Cell Res.* **1868**, 118885 (2021).

55. Chen, H., Zhao, R., Ge, M., Sun, Y., Li, Y. & Shan, L. Gliotoxin, a natural product with ferroptosis inducing properties. *Bioorg. Chem.* **133**, 106415 (2023).

56. Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., Patel, D. N., Bauer, A. J., Cantley, A. M., Yang, W. S., Morrison, B., 3rd & Stockwell, B. R. Ferroptosis: an iron-dependent form of nonapoptotic cell death. *Cell* **149**, 1060–1072 (2012).

57. Ma, J., Zhang, H., Chen, Y., Liu, X., Tian, J. & Shen, W. The Role of Macrophage Iron Overload and Ferroptosis in Atherosclerosis. *Biomolecules* **12**, (2022).

58. Shen, Q., Liang, M., Yang, F., Deng, Y. Z. & Naqvi, N. I. Ferroptosis contributes to developmental cell death in rice blast. *New Phytol.* **227**, 1831–1846 (2020).

59. Frąc, M., Jezierska-Tys, S. & Yaguchi, T. in *Advances in Agronomy* (ed. Sparks, D. L.) **132**, 161–204 (Academic Press, 2015).

60. Caggiano, G., Diella, G., Triggiano, F., Bartolomeo, N., Apollonio, F., Campanale, C., Lopizzo, M. & Montagna, M. T. Occurrence of Fungi in the Potable Water of Hospitals: A Public Health Threat. *Pathogens* **9**, (2020).
61. Anaissie, E. J., Stratton, S. L., Dignani, M. C., Summerbell, R. C., Rex, J. H., Monson, T. P., Spencer, T., Kasai, M., Francesconi, A. & Walsh, T. J. Pathogenic Aspergillus species recovered from a hospital water system: a 3-year prospective study. *Clin. Infect. Dis.* **34**, 780–789 (2002).
62. Belizario, J. A., Lopes, L. G. & Pires, R. H. Fungi in the indoor air of critical hospital areas: a review. *Aerobiologia* **37**, 379–394 (2021).
63. Tong, X., Xu, H., Zou, L., Cai, M., Xu, X., Zhao, Z., Xiao, F. & Li, Y. High diversity of airborne fungi in the hospital environment as revealed by meta-sequencing-based microbiome analysis. *Sci. Rep.* **7**, 39606 (2017).
64. Hawksworth, D. L. & Lücking, R. Fungal Diversity Revisited: 2.2 to 3.8 Million Species. *Microbiol Spectr* **5**, (2017).
65. Satoh, K., Makimura, K., Hasumi, Y., Nishiyama, Y., Uchida, K. & Yamaguchi, H. *Candida auris* sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. *Microbiol. Immunol.* **53**, 41–44 (2009).
66. Raja, H. A., Miller, A. N., Pearce, C. J. & Oberlies, N. H. Fungal Identification Using Molecular Tools: A Primer for the Natural Products Research Community. *J. Nat. Prod.* **80**, 756–770 (2017).
67. Chethana, K. W. T., Manawasinghe, I. S., Hurdeal, V. G., Bhunjun, C. S., Appadoo, M. A., Gentekaki, E., Raspé, O., Promputtha, I. & Hyde, K. D. What are fungal species and how to delineate them? *Fungal Divers.* **109**, 1–25 (2021).

68. Steinbach, W. J., Marr, K. A., Anaissie, E. J., Azie, N., Quan, S.-P., Meier-Kriesche, H.-U., Apewokin, S. & Horn, D. L. Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. *J. Infect.* **65**, 453–464 (2012).
69. Libkind, D., Čadež, N., Opulente, D. A., Langdon, Q. K., Rosa, C. A., Sampaio, J. P., Gonçalves, P., Hittinger, C. T. & Lachance, M. A. Towards yeast taxogenomics: lessons from novel species descriptions based on complete genome sequences. *FEMS Yeast Res.* **20**, (2020).
70. Steenwyk, J. L., Knowles, S., Bastos, R. W., Balamurugan, C., Rinker, D., Mead, M. E., Roberts, C. D., Raja, H. A., Li, Y., Colabardini, A. C., de Castro, P. A., Dos Reis, T. F., Canóvas, D., Sanchez, R. L., Lagrou, K., Torrado, E., Rodrigues, F., Oberlies, N. H., Zhou, X., Goldman, G. H. & Rokas, A. Evolutionary origin, population diversity, and diagnostics for a cryptic hybrid pathogen. *bioRxiv* (2023). doi:10.1101/2023.07.03.547508
71. Steenwyk, J. L., Balamurugan, C., Raja, H. A., Gonçalves, C., Li, N., Martin, F., Berman, J., Oberlies, N. H., Gibbons, J. G., Goldman, G. H., Geiser, D. M., Hibbett, D. S. & Rokas, A. Phylogenomics reveals extensive misidentification of fungal strains from the genus Aspergillus. *bioRxiv* (2022). doi:10.1101/2022.11.22.517304
72. Mayer, E. in *Evolution and anthropology: a centennial appraisal* (ed. Meggars, B. J.) 1–10 (Anthropological Society of Washington, 1959).
73. Menzel, P., Ng, K. L. & Krogh, A. Fast and sensitive taxonomic classification for metagenomics with Kaiju. *Nat. Commun.* **7**, 11257 (2016).
74. Kolmogorov, M., Yuan, J., Lin, Y. & Pevzner, P. A. Assembly of long, error-prone reads using repeat graphs. *Nat. Biotechnol.* **37**, 540–546 (2019).
75. Walker, B. J., Abeel, T., Shea, T., Priest, M., Abouelliel, A., Sakthikumar, S., Cuomo, C. A.,

Zeng, Q., Wortman, J., Young, S. K. & Earl, A. M. Pilon: an integrated tool for comprehensive microbial variant detection and genome assembly improvement. *PLoS One* **9**, e112963 (2014).

76. Simão, F. A., Waterhouse, R. M., Ioannidis, P., Kriventseva, E. V. & Zdobnov, E. M. BUSCO: assessing genome assembly and annotation completeness with single-copy orthologs. *Bioinformatics* **31**, 3210–3212 (2015).

77. Gurevich, A., Saveliev, V., Vyahhi, N. & Tesler, G. QUAST: quality assessment tool for genome assemblies. *Bioinformatics* **29**, 1072–1075 (2013).

78. Bowyer, P., Currin, A., Delneri, D. & Fraczek, M. G. Telomere-to-telomere genome sequence of the model mould pathogen *Aspergillus fumigatus*. *Nat. Commun.* **13**, 5394 (2022).

79. Creators Jonathan M. Palmer1 Jason Stajich2 Show affiliations 1. USDA Forest Service 2. University of California-Riverside. *Funannotate v1.8.1: Eukaryotic genome annotation*. doi:10.5281/zenodo.4054262

80. Smit, A. F. A., Hubley, R. & Green, P. RepeatMasker Open-4.0. 2013-2015. at <<http://www.repeatmasker.org>>

81. Grabherr, M. G., Haas, B. J., Yassour, M., Levin, J. Z., Thompson, D. A., Amit, I., Adiconis, X., Fan, L., Raychowdhury, R., Zeng, Q., Chen, Z., Mauceli, E., Hacohen, N., Gnirke, A., Rhind, N., di Palma, F., Birren, B. W., Nusbaum, C., Lindblad-Toh, K., Friedman, N. & Regev, A. Full-length transcriptome assembly from RNA-Seq data without a reference genome. *Nat. Biotechnol.* **29**, 644–652 (2011).

82. Chan, P. P. & Lowe, T. M. tRNAscan-SE: Searching for tRNA Genes in Genomic Sequences. *Methods Mol. Biol.* **1962**, 1–14 (2019).

83. Nierman, W. C., Pain, A., Anderson, M. J., Wortman, J. R., Kim, H. S., Arroyo, J., Berriman, M., Abe, K., Archer, D. B., Bermejo, C., Bennett, J., Bowyer, P., Chen, D., Collins, M., Coulsen, R., Davies, R., Dyer, P. S., Farman, M., Fedorova, N., Fedorova, N., Feldblyum, T. V., Fischer, R., Fosker, N., Fraser, A., García, J. L., García, M. J., Goble, A., Goldman, G. H., Gomi, K., Griffith-Jones, S., Gwilliam, R., Haas, B., Haas, H., Harris, D., Horiuchi, H., Huang, J., Humphray, S., Jiménez, J., Keller, N., Khouri, H., Kitamoto, K., Kobayashi, T., Konzack, S., Kulkarni, R., Kumagai, T., Lafon, A., Latgé, J.-P., Li, W., Lord, A., Lu, C., Majoros, W. H., May, G. S., Miller, B. L., Mohamoud, Y., Molina, M., Monod, M., Mouyna, I., Mulligan, S., Murphy, L., O'Neil, S., Paulsen, I., Peñalva, M. A., Pertea, M., Price, C., Pritchard, B. L., Quail, M. A., Rabbinowitsch, E., Rawlins, N., Rajandream, M.-A., Reichard, U., Renauld, H., Robson, G. D., Rodriguez de Córdoba, S., Rodríguez-Peña, J. M., Ronning, C. M., Rutter, S., Salzberg, S. L., Sanchez, M., Sánchez-Ferrero, J. C., Saunders, D., Seeger, K., Squares, R., Squares, S., Takeuchi, M., Tekaia, F., Turner, G., Vazquez de Aldana, C. R., Weidman, J., White, O., Woodward, J., Yu, J.-H., Fraser, C., Galagan, J. E., Asai, K., Machida, M., Hall, N., Barrell, B. & Denning, D. W. Genomic sequence of the pathogenic and allergenic filamentous fungus *Aspergillus fumigatus*. *Nature* **438**, 1151–1156 (2005).

84. Edgar, R. C. Muscle5: High-accuracy alignment ensembles enable unbiased assessments of sequence homology and phylogeny. *Nat. Commun.* **13**, 6968 (2022).

85. Minh, B. Q., Schmidt, H. A., Chernomor, O., Schrempf, D., Woodhams, M. D., von Haeseler, A. & Lanfear, R. IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era. *Mol. Biol. Evol.* **37**, 1530–1534 (2020).

86. Sheikhzadeh, S., Schranz, M. E., Akdel, M., de Ridder, D. & Smit, S. PanTools:

representation, storage and exploration of pan-genomic data. *Bioinformatics* **32**, i487–i493 (2016).

87. Jonkheer, E. M., van Workum, D.-J. M., Sheikhzadeh Anari, S., Brankovics, B., de Haan, J. R., Berke, L., van der Lee, T. A. J., de Ridder, D. & Smit, S. PanTools v3: functional annotation, classification and phylogenomics. *Bioinformatics* **38**, 4403–4405 (2022).

88. Stajich, J. E., Harris, T., Brunk, B. P., Brestelli, J., Fischer, S., Harb, O. S., Kissinger, J. C., Li, W., Nayak, V., Pinney, D. F., Stoeckert, C. J., Jr & Roos, D. S. FungiDB: an integrated functional genomics database for fungi. *Nucleic Acids Res.* **40**, D675–81 (2012).

89. Buchfink, B., Reuter, K. & Drost, H.-G. Sensitive protein alignments at tree-of-life scale using DIAMOND. *Nat. Methods* **18**, 366–368 (2021).

90. Auwera, G., Van de, A. & O'Connor, B. D. *Genomics in the Cloud: Using Docker, GATK, and WDL in Terra*. (Beijing Boston Farnham Sebastopol Tokyo: O'Reilly, 2020).

91. Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R. & 1000 Genome Project Data Processing Subgroup. The Sequence Alignment/Map format and SAMtools. *Bioinformatics* **25**, 2078–2079 (2009).

92. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* **25**, 1754–1760 (2009).

93. Danecek, P., Auton, A., Abecasis, G., Albers, C. A., Banks, E., DePristo, M. A., Handsaker, R. E., Lunter, G., Marth, G. T., Sherry, S. T., McVean, G., Durbin, R. & 1000 Genomes Project Analysis Group. The variant call format and VCFtools. *Bioinformatics* **27**, 2156–2158 (2011).

94. Lofgren, L. A., Ross, B. S., Cramer, R. A. & Stajich, J. E. The pan-genome of *Aspergillus fumigatus* provides a high-resolution view of its population structure revealing high levels of

lineage-specific diversity driven by recombination | PLOS Biology. *PLoS Biol.* **20**, e3001890 (2022).

95. Alexander, D. H., Novembre, J. & Lange, K. Fast model-based estimation of ancestry in unrelated individuals. *Genome Res.* **19**, 1655–1664 (2009).

96. Chang, C. C., Chow, C. C., Tellier, L. C., Vattikuti, S., Purcell, S. M. & Lee, J. J. Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience* **4**, 7 (2015).

97. Terlouw, B. R., Blin, K., Navarro-Muñoz, J. C., Avalon, N. E., Chevrette, M. G., Egbert, S., Lee, S., Meijer, D., Recchia, M. J. J., Reitz, Z. L., van Santen, J. A., Selem-Mojica, N., Tørring, T., Zaroubi, L., Alanjary, M., Aleti, G., Aguilar, C., Al-Salihi, S. A. A., Augustijn, H. E., Avelar-Rivas, J. A., Avitia-Domínguez, L. A., Barona-Gómez, F., Bernaldo-Agüero, J., Bielinski, V. A., Biermann, F., Booth, T. J., Carrion Bravo, V. J., Castelo-Branco, R., Chagas, F. O., Cruz-Morales, P., Du, C., Duncan, K. R., Gavriilidou, A., Gayrard, D., Gutiérrez-García, K., Haslinger, K., Helfrich, E. J. N., van der Hooft, J. J. J., Jati, A. P., Kalkreuter, E., Kalyvas, N., Kang, K. B., Kautsar, S., Kim, W., Kunjapur, A. M., Li, Y.-X., Lin, G.-M., Loureiro, C., Louwen, J. J. R., Louwen, N. L. L., Lund, G., Parra, J., Philmus, B., Pourmohsenin, B., Pronk, L. J. U., Rego, A., Rex, D. A. B., Robinson, S., Rosas-Becerra, L. R., Roxborough, E. T., Schorn, M. A., Scobie, D. J., Singh, K. S., Sokolova, N., Tang, X., Udwary, D., Vigneshwari, A., Vind, K., Vromans, S. P. J. M., Waschulin, V., Williams, S. E., Winter, J. M., Witte, T. E., Xie, H., Yang, D., Yu, J., Zdouc, M., Zhong, Z., Collemare, J., Linington, R. G., Weber, T. & Medema, M. H. MIBiG 3.0: a community-driven effort to annotate experimentally validated biosynthetic gene clusters. *Nucleic Acids Res.* **51**, D603–D610 (2023).

98. Blin, K., Shaw, S., Kloosterman, A. M., Charlop-Powers, Z., van Wezel, G. P., Medema, M. H. & Weber, T. antiSMASH 6.0: improving cluster detection and comparison capabilities. *Nucleic Acids Res.* **49**, W29–W35 (2021).

99. FastQC. Preprint at <https://qubeshub.org/resources/fastqc> (2015)

100. Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics* **30**, 2114–2120 (2014).

101. Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M. & Gingeras, T. R. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15–21 (2013).

102. Anders, S., Pyl, P. T. & Huber, W. HTSeq--a Python framework to work with high-throughput sequencing data. *Bioinformatics* **31**, 166–169 (2015).

103. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550 (2014).

104. Tisch, D. & Schmoll, M. Light regulation of metabolic pathways in fungi. *Appl. Microbiol. Biotechnol.* **85**, 1259–1277 (2010).

105. Al Subeh, Z. Y., Raja, H. A., Monro, S., Flores-Bocanegra, L., El-Elimat, T., Pearce, C. J., McFarland, S. A. & Oberlies, N. H. Enhanced Production and Anticancer Properties of Photoactivated Perylenequinones. *J. Nat. Prod.* **83**, 2490–2500 (2020).

106. Knowles, S. L., Roberts, C. D., Augustinović, M., Flores-Bocanegra, L., Raja, H. A., Heath-Borrero, K. N., Burdette, J. E., Falkingham, J. O., Iii, Pearce, C. J. & Oberlies, N. H. Opportunities and Limitations for Assigning Relative Configurations of Antibacterial Bislactones using GIAO NMR Shift Calculations. *J. Nat. Prod.* **84**, 1254–1260 (2021).

107. El-Elimat, T., Figueroa, M., Raja, H. A., Alnabulsi, S. M. & Oberlies, N. H. Coumarins,

dihydroisocoumarins, a dibenzo- $\alpha$ -pyrone, a meroterpenoid, and a merodrimane from *Talaromyces amestolkiae*. *Tetrahedron Lett.* **72**, (2021).

108. Paguigan, N. D., El-Elimat, T., Kao, D., Raja, H. A., Pearce, C. J. & Oberlies, N. H. Enhanced dereplication of fungal cultures via use of mass defect filtering. *J. Antibiot.* **70**, 553–561 (2017).

109. Marim, F. M., Silveira, T. N., Lima, D. S., Jr & Zamboni, D. S. A method for generation of bone marrow-derived macrophages from cryopreserved mouse bone marrow cells. *PLoS One* **5**, e15263 (2010).

## TABLES

**Table 1: Strains used in this study**

VU Strain ID	CBS strain ID	Country of origin	Substrate	Year isolated	Isolated by
DTO1	CBS 118456	Morocco	soil	2005	Jos Houbraken
DTO2	CBS 150748	Thailand	Soil from pineapple field	2005	Jos Houbraken
DTO3	CBS 150749	Spain	Strawberries	2006	Jos Houbraken
DTO4	CBS 150750	Imported in the Netherlands	Heat treated coconut milk	2006	Jos Houbraken
DTO5	CBS 150751	The Netherlands	Cardboard	2006	Jos Houbraken
DTO6	CBS 150752	The Netherlands	Cardboard	2006	Jos Houbraken
DTO7	CBS 420.96	Nepal	soil under <i>Zea mays</i>	unkn.	B. v.d. Pol
DTO8	CBS 150753	Unknown	Soil (glacial)	2008	Jos Houbraken
DTO9	CBS 147335	The Netherlands	Strawberry jam	2011	Jos Houbraken
DTO10	CBS 150754	The Netherlands	Ingredient, maize based	2011	Martin Meijer
DTO11	CBS 54465 (NRRL181)	Unknown	canned apples	1923	C. Wehmer
DTO12	CBS 150755	Turkey	Soil	2014	Rasime Demirel
DTO13	CBS 150756	South Africa	Soil	2015	Martin Meijer
DTO14	CBS 150757	South Africa	Soil under eucalyptus	2015	Martin Meijer
DTO15	CBS 150759	Belgium	Nickel hydroxide carbonate	2015	Martin Meijer
DTO16	CBS 150758	Italy	Food organic material from biodigester	2018	Simone Di Piazza

**Table 2: Variation in the presence/absence of select BGCs and their secondary metabolite compounds. Presence (+) and absence or lack of detection (-) of BGCs and their compounds indicated as (BGC/compound).**

	Gliotoxin	Fumitremorgin B	Verruculogen	Trypacidin	HAS	Pseurotin	Fumagillin
MIBiG BGC ID	0000361	0000356		0001403	0000372	0001037	0001067
DTO1	+/+	+/+	+/+	-/-	+/-	-/-	-/-*
DTO2	+/+	+/+	+/+	+/-	+/-	-/-	-/-
DTO3	+/-	+/-	+/-	+/-	+/-	-/-	-/-*
DTO4	+/+	+/-	+/-	+/-	+/-	-/-	-/-*
DTO5	+/-	+/+	+/-	+/-	+/-	-/-	-/-*
DTO6	+/-	+/+	+/-	+/-	+/-	-/-	-/-*
DTO7	+/+	+/-	+/-	-/-	+/*	-/-	-/-
DTO8	+/+	+/+	+/+	+/-	+/-	-/-	-/-*
DTO9	+/-	+/-	+/-	+/-	+/-	-/-	-/-
DTO10	+/-	-/-	-/-	+/-	+/-	-/-	-/-*
DTO11	+/-	+/-	+/-	+/-	+/*	-/-	-/-
DTO12	+/-	+/+	+/+	+/-	+/*	-/-	-/-
DTO13	+/-	+/-	+/-	+/-	+/*	-/-	-/-
DTO14	+/+	+/-	+/-	+/-	+/*	-/-	-/-

DTO15	+/+	+/+	+/-	+/-	+/+	-/-	-/-
DTO16	+/+	+/+	+/+	+/-	+/+	-/-	-/-
NRRL 181**	+/+	+/+	+/+	+/-	NA	-/-	-/-
NRRL 4585**	+/+	+/+	+/+	-/-	NA	-/-	-/-
NRRL 4161**	+/+	+/+	+/+	-/-	NA	-/-	-/-

\* Detection of intermediate metabolites suggest that part of the pathway may be functional and/or annotation of BGC is incomplete.

\*\* Results reported from previous genomic and metabolomic analysis of three *A. fischeri* strains<sup>20</sup>.